---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-332742"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2026-08-04T20:03:07+00:00"
generated_at: "2026-08-04T20:05:00.145906+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics terminates Cambridge lease early, reduces facilities costs

## Summary
- Surrenders 21,295 sq ft immediately; remaining 47,341 sq ft vacated by Dec 31, 2026 (original lease end Jan 13, 2031).
- Total consideration: $2.2M LC increase, $3.85M termination fee, and 103,520 shares of stock valued at $500k.
- Lease termination eliminates primary restoration obligations and reduces ongoing annual facilities costs.
- Stock issued at $4.83 per share, registered on Form S-3, freely tradeable upon issuance.

## SEC filing metadata
- accession: 0001193125-26-332742
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2026-08-04T20:03:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/0001193125-26-332742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/d133274d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-332742
- JSON: https://secwatch.observer/filing/0001193125-26-332742.json
- Plain text: https://secwatch.observer/filing/0001193125-26-332742.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.